TSX · Biotechnology · CAD
Sernova Biotherapeutics Inc (SVA.TO) Stock Analysis
Sernova Biotherapeutics Inc (SVA.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
SVA.TO Key Statistics
As of Oct 21, 2026Trading
- Open
- CA$0.11
- Previous Close
- CA$0.11
- Day's Range
- 0.11–0.12
- 52-Week Range
- 0.09–0.20
- Volume
- 98.36K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.64
Valuation
- Market Cap
- CA$45.32M
Financials (FY)
- Revenue (FY)
- CA$0.00
- Net Income (FY)
- −CA$15.74M
- Shares Outstanding
- 377.64M
- 1-Year Return
- −29.41%
Dividend and dates
- Avg Volume
- 212.46K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, SVA.TO closed at CA$0.12, −29.41% over 1 year.
Sernova Biotherapeutics Inc (SVA.TO) has a market capitalization of CA$45.32M.
In fiscal 2025, SVA.TO reported revenue of CA$0.00.
SVA.TO Stock Return by Calendar Year
Sernova Biotherapeutics Inc (SVA.TO) 10-year return: what CA$10,000 became
- 1 year
- CA$10,000 CA$7,059
- −29.41%
- 5 years
- CA$10,000 CA$960
- −90.40%
- 10 years
- CA$10,000 CA$4,286
- −57.14%
If you had invested CA$10,000 in Sernova Biotherapeutics Inc (SVA.TO) 10 years ago, at the close on October 21, 2016, it would have been worth CA$4,286 at the close on October 21, 2026: −57.14% in total, −8.12% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −7.69% |
| 2025 | −43.48% |
| 2024 | −67.14% |
| 2023 | −11.39% |
| 2022 | −56.59% |
| 2021 | +171.64% |
| 2020 | +294.12% |
| 2019 | −15.00% |
| 2018 | −52.38% |
| 2017 | +40.00% |
| 2016 (partial year) | −6.25% |
As of October 21, 2026.
SVA.TO Revenue and Earnings by Fiscal Year
FY ends October| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | CA$0.00 | −CA$15.74M | — |
| 2024 | CA$0.00 | −CA$32.19M | — |
| 2023 | CA$0.00 | −CA$39.00M | — |
| 2022 | CA$0.00 | −CA$24.42M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | CA$0.00 | — | −CA$15.02M | −CA$15.74M | — |
| 2024 | CA$0.00 | — | −CA$31.66M | −CA$32.19M | — |
| 2023 | CA$0.00 | — | −CA$40.50M | −CA$39.00M | — |
| 2022 | CA$0.00 | — | −CA$24.75M | −CA$24.42M | — |
Annual figures as reported, in the company's reporting currency. As of October 31, 2025.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B